annual EBITDA:
$656.54M+$204.59M(+45.27%)Summary
- As of today (June 22, 2025), HALO annual EBITDA is $656.54 million, with the most recent change of +$204.59 million (+45.27%) on December 31, 2024.
- During the last 3 years, HALO annual EBITDA has risen by +$397.50 million (+153.45%).
- HALO annual EBITDA is now at all-time high.
Performance
HALO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$168.80M-$34.37M(-16.92%)Summary
- As of today (June 22, 2025), HALO quarterly EBITDA is $168.80 million, with the most recent change of -$34.37 million (-16.92%) on March 31, 2025.
- Over the past year, HALO quarterly EBITDA has increased by +$48.06 million (+39.81%).
- HALO quarterly EBITDA is now -16.92% below its all-time high of $203.17 million, reached on December 31, 2024.
Performance
HALO quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$704.60M+$48.06M(+7.32%)Summary
- As of today (June 22, 2025), HALO TTM EBITDA is $704.60 million, with the most recent change of +$48.06 million (+7.32%) on March 31, 2025.
- Over the past year, HALO TTM EBITDA has increased by +$209.15 million (+42.21%).
- HALO TTM EBITDA is now at all-time high.
Performance
HALO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
HALO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +45.3% | +39.8% | +42.2% |
| 3 y3 years | +153.4% | +119.4% | +130.9% |
| 5 y5 years | +1260.9% | +10000.0% | +1228.2% |
HALO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +153.4% | -16.9% | +269.7% | at high | +174.3% |
| 5 y | 5-year | at high | +1260.9% | -16.9% | >+9999.0% | at high | +1228.2% |
| alltime | all time | at high | +926.1% | -16.9% | +668.6% | at high | +846.2% |
HALO EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $168.80M(-16.9%) | $704.60M(+7.3%) |
| Dec 2024 | $656.54M(+45.3%) | $203.17M(+6.9%) | $656.54M(+13.1%) |
| Sep 2024 | - | $190.03M(+33.3%) | $580.46M(+11.7%) |
| Jun 2024 | - | $142.60M(+18.1%) | $519.77M(+4.9%) |
| Mar 2024 | - | $120.74M(-5.0%) | $495.45M(+9.6%) |
| Dec 2023 | $451.95M(+43.2%) | $127.09M(-1.7%) | $451.95M(+11.0%) |
| Sep 2023 | - | $129.34M(+9.4%) | $407.33M(+4.9%) |
| Jun 2023 | - | $118.28M(+53.1%) | $388.42M(+23.0%) |
| Mar 2023 | - | $77.24M(-6.3%) | $315.80M(+0.1%) |
| Dec 2022 | $315.51M(+21.8%) | $82.47M(-25.3%) | $315.51M(+8.5%) |
| Sep 2022 | - | $110.42M(+141.8%) | $290.67M(+13.2%) |
| Jun 2022 | - | $45.66M(-40.7%) | $256.86M(-15.8%) |
| Mar 2022 | - | $76.95M(+33.5%) | $305.20M(+17.8%) |
| Dec 2021 | $259.04M(+69.3%) | $57.64M(-24.8%) | $259.04M(-7.6%) |
| Sep 2021 | - | $76.61M(-18.5%) | $280.49M(+14.0%) |
| Jun 2021 | - | $94.00M(+205.3%) | $245.94M(+33.9%) |
| Mar 2021 | - | $30.79M(-61.1%) | $183.64M(+20.1%) |
| Dec 2020 | $152.96M(-370.5%) | $79.08M(+88.0%) | $152.96M(+246.1%) |
| Sep 2020 | - | $42.06M(+32.7%) | $44.19M(-323.3%) |
| Jun 2020 | - | $31.70M(>+9900.0%) | -$19.79M(-68.3%) |
| Mar 2020 | - | $113.00K(-100.4%) | -$62.46M(+10.4%) |
| Dec 2019 | -$56.56M(-4.7%) | -$29.69M(+35.4%) | -$56.56M(+132.4%) |
| Sep 2019 | - | -$21.92M(+100.0%) | -$24.33M(-4.1%) |
| Jun 2019 | - | -$10.96M(-282.3%) | -$25.36M(-20.4%) |
| Mar 2019 | - | $6.01M(+137.1%) | -$31.87M(-46.3%) |
| Dec 2018 | -$59.36M(-169.2%) | $2.54M(-111.0%) | -$59.36M(-190.5%) |
| Sep 2018 | - | -$22.95M(+31.4%) | $65.60M(-33.0%) |
| Jun 2018 | - | -$17.47M(-18.7%) | $97.92M(+7.7%) |
| Mar 2018 | - | -$21.48M(-116.8%) | $90.91M(+6.0%) |
| Dec 2017 | $85.75M(-207.9%) | $127.50M(+1261.8%) | $85.75M(-235.4%) |
| Sep 2017 | - | $9.36M(-138.3%) | -$63.31M(-33.0%) |
| Jun 2017 | - | -$24.47M(-8.1%) | -$94.43M(+4.2%) |
| Mar 2017 | - | -$26.64M(+23.5%) | -$90.66M(+14.1%) |
| Dec 2016 | -$79.47M(+213.5%) | -$21.57M(-0.9%) | -$79.47M(+53.3%) |
| Sep 2016 | - | -$21.75M(+5.1%) | -$51.83M(-1.9%) |
| Jun 2016 | - | -$20.70M(+34.0%) | -$52.83M(+92.7%) |
| Mar 2016 | - | -$15.45M(-354.2%) | -$27.42M(+8.1%) |
| Dec 2015 | -$25.35M(-58.5%) | $6.08M(-126.7%) | -$25.35M(-27.3%) |
| Sep 2015 | - | -$22.76M(-582.9%) | -$34.87M(+14.1%) |
| Jun 2015 | - | $4.71M(-135.2%) | -$30.55M(-38.5%) |
| Mar 2015 | - | -$13.39M(+289.4%) | -$49.65M(-18.7%) |
| Dec 2014 | -$61.03M(-22.7%) | -$3.44M(-81.4%) | -$61.03M(-22.3%) |
| Sep 2014 | - | -$18.44M(+28.2%) | -$78.52M(+0.4%) |
| Jun 2014 | - | -$14.38M(-42.0%) | -$78.22M(-8.6%) |
| Mar 2014 | - | -$24.77M(+18.4%) | -$85.61M(+8.4%) |
| Dec 2013 | -$78.98M | -$20.93M(+15.4%) | -$78.98M(+27.0%) |
| Sep 2013 | - | -$18.14M(-16.7%) | -$62.17M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$21.77M(+20.0%) | -$63.75M(+14.4%) |
| Mar 2013 | - | -$18.14M(+340.1%) | -$55.74M(+6.2%) |
| Dec 2012 | -$52.47M(+181.0%) | -$4.12M(-79.1%) | -$52.47M(-21.1%) |
| Sep 2012 | - | -$19.72M(+43.4%) | -$66.46M(+60.7%) |
| Jun 2012 | - | -$13.75M(-7.6%) | -$41.35M(+70.7%) |
| Mar 2012 | - | -$14.88M(-17.8%) | -$24.22M(+29.7%) |
| Dec 2011 | -$18.67M(-64.6%) | -$18.11M(-436.0%) | -$18.67M(+3.2%) |
| Sep 2011 | - | $5.39M(+59.4%) | -$18.10M(-49.1%) |
| Jun 2011 | - | $3.38M(-136.2%) | -$35.56M(-29.9%) |
| Mar 2011 | - | -$9.33M(-46.8%) | -$50.71M(-3.9%) |
| Dec 2010 | -$52.75M(-7.5%) | -$17.54M(+45.3%) | -$52.75M(+11.1%) |
| Sep 2010 | - | -$12.07M(+2.6%) | -$47.49M(-3.1%) |
| Jun 2010 | - | -$11.76M(+3.4%) | -$48.99M(-9.2%) |
| Mar 2010 | - | -$11.38M(-7.4%) | -$53.96M(-5.4%) |
| Dec 2009 | -$57.01M(+15.4%) | -$12.28M(-9.5%) | -$57.01M(-7.2%) |
| Sep 2009 | - | -$13.57M(-18.9%) | -$61.47M(+4.5%) |
| Jun 2009 | - | -$16.73M(+16.0%) | -$58.82M(+10.5%) |
| Mar 2009 | - | -$14.43M(-13.8%) | -$53.21M(+7.7%) |
| Dec 2008 | -$49.39M(+79.1%) | -$16.74M(+53.3%) | -$49.39M(+16.6%) |
| Sep 2008 | - | -$10.92M(-1.9%) | -$42.36M(+7.0%) |
| Jun 2008 | - | -$11.13M(+4.9%) | -$39.60M(+15.8%) |
| Mar 2008 | - | -$10.61M(+9.2%) | -$34.19M(+24.0%) |
| Dec 2007 | -$27.57M(+79.8%) | -$9.71M(+19.1%) | -$27.57M(+22.8%) |
| Sep 2007 | - | -$8.16M(+42.9%) | -$22.46M(+24.3%) |
| Jun 2007 | - | -$5.71M(+43.0%) | -$18.06M(+15.0%) |
| Mar 2007 | - | -$3.99M(-13.1%) | -$15.71M(+2.4%) |
| Dec 2006 | -$15.34M(+14.9%) | -$4.60M(+22.2%) | -$15.34M(+7.5%) |
| Sep 2006 | - | -$3.76M(+12.1%) | -$14.27M(+0.3%) |
| Jun 2006 | - | -$3.36M(-7.2%) | -$14.23M(+3.4%) |
| Mar 2006 | - | -$3.62M(+2.6%) | -$13.75M(+3.0%) |
| Dec 2005 | -$13.36M(+49.0%) | -$3.53M(-5.2%) | -$13.36M(+8.4%) |
| Sep 2005 | - | -$3.72M(+29.0%) | -$12.32M(+4.2%) |
| Jun 2005 | - | -$2.88M(-10.4%) | -$11.82M(+7.5%) |
| Mar 2005 | - | -$3.22M(+29.4%) | -$11.00M(+22.7%) |
| Dec 2004 | -$8.96M(<-9900.0%) | -$2.49M(-23.0%) | -$8.96M(+64.7%) |
| Sep 2004 | - | -$3.23M(+56.9%) | -$5.44M(+109.3%) |
| Jun 2004 | - | -$2.06M(+73.6%) | -$2.60M(+190.1%) |
| Mar 2004 | - | -$1.19M(-214.9%) | -$896.50K(-1721.2%) |
| Dec 2003 | $0.00(0.0%) | $1.03M(-366.3%) | $55.30K(-105.8%) |
| Sep 2003 | - | -$387.70K(+9.1%) | -$958.70K(+64.3%) |
| Jun 2003 | - | -$355.20K(+51.6%) | -$583.60K(+136.6%) |
| Mar 2003 | - | -$234.30K(-1366.5%) | -$246.70K(<-9900.0%) |
| Dec 2002 | $0.00(-100.0%) | $18.50K(-246.8%) | $0.00(-100.0%) |
| Sep 2002 | - | -$12.60K(-31.1%) | -$18.50K(+213.6%) |
| Jun 2002 | - | -$18.30K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40K | $12.40K |
| Dec 2001 | -$39.70K | - | - |
FAQ
- What is Halozyme Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual EBITDA year-on-year change?
- What is Halozyme Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly EBITDA year-on-year change?
- What is Halozyme Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM EBITDA year-on-year change?
What is Halozyme Therapeutics annual EBITDA?
The current annual EBITDA of HALO is $656.54M
What is the all time high annual EBITDA for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual EBITDA is $656.54M
What is Halozyme Therapeutics annual EBITDA year-on-year change?
Over the past year, HALO annual EBITDA has changed by +$204.59M (+45.27%)
What is Halozyme Therapeutics quarterly EBITDA?
The current quarterly EBITDA of HALO is $168.80M
What is the all time high quarterly EBITDA for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly EBITDA is $203.17M
What is Halozyme Therapeutics quarterly EBITDA year-on-year change?
Over the past year, HALO quarterly EBITDA has changed by +$48.06M (+39.81%)
What is Halozyme Therapeutics TTM EBITDA?
The current TTM EBITDA of HALO is $704.60M
What is the all time high TTM EBITDA for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM EBITDA is $704.60M
What is Halozyme Therapeutics TTM EBITDA year-on-year change?
Over the past year, HALO TTM EBITDA has changed by +$209.15M (+42.21%)